Kantonsspital St.Gallen
login

publications

Christoph Driessen

title  
 
van Kempen T S, Leijten E F A, Lindenbergh M F S, Nordkamp M O, Driessen C, Lebbink R J, Baerlecken N, Witte T, Radstake T R D J, Boes M. Impaired proteolysis by SPPL2a causes CD74 fragment accumulation that can be recognized by anti-CD74 autoantibodies in human ankylosing spondylitis. Eur J Immunol 2020; 50:1209-1219.
   
Cavo M, Gay F, Beksac M, Pantani L, Petrucci M T, Dimopoulos M A, Dozza L, van der Holt B, Zweegman S, Oliva S, van der Velden V H J, Zamagni E, Palumbo G A, Patriarca F, Montefusco V, Galli M, Maisnar V, Gamberi B, Hansson M, Belotti A, Pour L, Ypma P, Grasso M, Croockewit A, Ballanti S, Offidani M, Vincelli I D, Zambello R, Liberati A M, Andersen N F, Broijl A, Troia R, Pascarella A, Benevolo G, Levin M D, Bos G, Ludwig H, Aquino S, Morelli A M, Wu K L, Boersma R, Hájek R, Durian M, von dem Borne P A, Caravita di Toritto T, Zander T, Driessen C, Specchia G, Waage A, Gimsing P, Mellqvist U H, van Marwijk Kooy M, Minnema M, Mandigers C, Cafro A M, Palmas A, Carvalho S, Spencer A, Boccadoro M, Sonneveld P. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol 2020; 7:e456-e468.
   
Byrgazov K, Kraus M, Besse A, Slipicevic A, Lehmann F, Driessen C, Besse L. Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs. Leuk Res 2020; 101:106499.
   
Ludwig H, Boccadoro M, Moreau P, San-Miguel J, Cavo M, Pawlyn C, Zweegman S, Facon T, Driessen C, Hájek R, Dimopoulos M A, Gay F, Avet-Loiseau H, Terpos E, Zojer N, Mohty M, Mateos M V, Einsele H, Delforge M, Caers J, Weisel K, Jackson G, Garderet L, Engelhardt M, van de Donk N, Leleu X, Goldschmidt H, Beksac M, Nijhof I, Abildgaard N, Bringhen S, Sonneveld P. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. Leukemia 2020; 35:31-44.
   
Lin Y H T, Way G P, Barwick B G, Mariano M C, Marcoulis M, Ferguson I D, Driessen C, Boise L H, Greene C S, Wiita A P. Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma. Blood Adv 2019; 3:3214-3227.
   
Besse L, Besse A, Mendez-Lopez M, Vasickova K, Sedlackova M, Vanhara P, Kraus M, Bader J, Ferreira R B, Castellano R K, Law B K, Driessen C. A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis. Haematologica 2019; 104:e415-e419.
   
Mendez-Lopez M, Sutter T, Driessen C, Besse L. HIV protease inhibitors for the treatment of multiple myeloma. Clin Adv Hematol Oncol 2019; 17:615-623.
   
Plummer C, Driessen C, Szabo Z, Mateos M V. Management of cardiovascular risk in patients with multiple myeloma. Blood Cancer J 2019; 9:26.
   
Brünnert D, Kraus M, Stühmer T, Kirner S, Heiden R, Goyal P, Driessen C, Bargou R C, Chatterjee M. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma. Biochim Biophys Acta Mol Basis Dis 2019; 1865:1666-1676.
   
Hitz F, Kraus M, Pabst T, Hess D, Besse L, Silzle T, Novak U, Seipel K, Rondeau S, Stüdeli S, Vilei S B, Samaras P, Mey U, Driessen C, Swiss Group for Clinical Cancer Research SAKK . Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10). Blood Cancer J 2019; 9:70.
   
Samaras P, Bargetzi M, Betticher D C, Driessen C, Duchosal M A, Heim D, Ketterer N, Lerch E, Matthes T, Mey U, Pabst T, Schmidt A, Taverna C, Zander T, Renner C. Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. Swiss Med Wkly 2019; 149:w20031.
   
Joerger M, gueller u, Bastian S, Driessen C, von Moos R. Prolonged tumor response associated with sequential immune checkpoint inhibitor combination treatment and regorafenib in a patient with advanced pretreated hepatocellular carcinoma. J Gastrointest Oncol 2019; 10:373-378.
   
Amodio N, Gallo Cantafio M E, Botta C, Agosti V, Federico C, Caracciolo D, Ronchetti D, Rossi M, Driessen C, Neri A, Tagliaferri P, Tassone P. Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. Cancers (Basel) 2019; 11:.
   
Bringhen S, Milan A, D'Agostino M, Ferri C, Wäsch R, Gay F, Larocca A, Offidani M, Zweegman S, Terpos E, Goldschmidt H, Cavo M, Ludwig H, Driessen C, Auner H W, Caers J, Gramatzki M, Dimopoulos M A, Boccadoro M, Einsele H, Sonneveld P, Engelhardt M. Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. J Intern Med 2019; 286:63-74.
   
Schett A, Rothschild S I, Curioni-Fontecedro A, Krähenbühl S, Früh M, Schmid S, Driessen C, Joerger M. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC. Cancer Chemother Pharmacol 2019; 85:121-131.
   
Xin B T, Huber E M, de Bruin G, Heinemeyer W, Maurits E, Espinal C, Du Y, Janssens M, Weyburne E S, Kisselev A F, Florea B I, Driessen C, van der Marel G A, Groll M, Overkleeft H S. Structure-Based Design of Inhibitors Selective for Human Proteasome β2c or β2i Subunits. J Med Chem 2019; 62:1626-1642.
   
Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hájek R, Mohty M, Cavo M, Dimopoulos M A, San-Miguel J F, Terpos E, Zweegman S, Garderet L, Mateos M V, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk N W C J, Waage A, Beksac M, Mellqvist U H, Engelhardt M, Caers J, Driessen C, Bladé J, Sonneveld P. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia 2018;.
   
Downey-Kopyscinski S, Daily E W, Gautier M, Bhatt A, Florea B I, Mitsiades C S, Richardson P G, Driessen C, Overkleeft H S, Kisselev A F. An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors. Blood Adv 2018; 2:2443-2451.
   
abt d, Besse A, Sedlarikova L, Kraus M, Bader J, Silzle T, Vodinska M, Slaby O, Schmid H P, Engeler D S, Driessen C, Besse L. Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir. BJU Int 2018; 121:600-9.
   
abt d, Besse A, Sedlarikova L, Kraus M, Bader J, Silzle T, Vodinska M, Slaby O, Schmid H P, Engeler D S, Driessen C, Besse L. Verbesserte Wirksamkeit von Proteasom-Inhibitoren in der Behandlung des Nierenzellkarzinoms durch die Kombination mit den HIV-Protease-Inhibitoren Lopinavir und Nelfinavir. German Medicale Science, www.egms.de 2018;.
   
Caers J, Garderet L, Kortüm K M, O'Dwyer M E, van de Donk N W C J, Binder M, Dold S M, Gay F, Corre J, Beguin Y, Ludwig H, Larocca A, Driessen C, Dimopoulos M A, Boccadoro M, Gramatzki M, Zweegman S, Einsele H, Cavo M, Goldschmidt H, Sonneveld P, Delforge M, Auner H W, Terpos E, Engelhardt M. An European Myeloma Network recommendation on tools for diagnosis and monitoring of multiple myeloma: what to use and when. Haematologica 2018;.
   
Driessen C, Müller R, Novak U, Cantoni N, Betticher D, Mach N, Rüfer A, Mey U, Samaras P, Ribi K, Besse L, Besse A, Berset C, Rondeau S, Hawle H, Hitz F, Pabst T, Zander T. Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma. Blood 2018;.
   
Barrio S, Stühmer T, Da-Viá M, Barrio-Garcia C, Lehners N, Besse A, Cuenca I, Garitano-Trojaola A, Fink S, Leich E, Chatterjee M, Driessen C, Martinez-Lopez J, Rosenwald A, Beckmann R, Bargou R C, Braggio E, Stewart A K, Raab M S, Einsele H, Kortüm K M. Spectrum and functional validation of PSMB5 mutations in multiple myeloma. Leukemia 2018;.
   
Besse A, Besse L, Kraus M, Mendez-Lopez M, Bader J, Xin B T, de Bruin G, Maurits E, Overkleeft H S, Driessen C. Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors. Cell Chem Biol 2018;.
   
Aeppli S, Driessen C, Graf L, Hitz F. Systemic treatment of a patient with relapsed and refractory extranodal NK/T-cell lymphoma (ENKL) and meningeosis leukemica with daratumumab. Hematol Oncol 2018;.
   
Besse A, Stolze S C, Rasche L, Weinhold N, Morgan G J, Kraus M, Bader J, Overkleeft H S, Besse L, Driessen C. Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma. Leukemia 2017; 32:391-401.
   
abt d, Besse A, Sedlarikova L, Kraus M, Bader J, Silzle T, Vodinska M, Slaby O, Schmid H P, Engeler D S, Driessen C, Besse L. Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir. BJU Int 2017;.
   
Skrott Z, Mistrik M, Andersen K K, Friis S, Majera D, Gursky J, Ozdian T, Bartkova J, Turi Z, Moudry P, Kraus M, Michalova M, Vaclavkova J, Dzubak P, Vrobel I, Pouckova P, Sedlacek J, Miklovicova A, Kutt A, Li J, Mattova J, Driessen C, Dou Q P, Olsen J, Hajduch M, Cvek B, Deshaies R J, Bartek J. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. Nature 2017; 552:194-199.
   
Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos M A, San-Miguel J F, Terpos E, Zweegman S, Garderet L, Mateos M V, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk N W C J, Waage A, Beksac M, Mellqvist U H, Engelhardt M, Caers J, Driessen C, Sonneveld P. Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network. Leukemia 2017;.
   
Le Moigne R, Aftab B T, Djakovic S, Dhimolea E, Valle E, Murnane M, King E M, Soriano F, Menon M K, Wu Z Y, Wong S T, Lee G J, Yao B, Wiita A P, Lam C, Rice J, Wang J, Chesi M, Bergsagel P L, Kraus M, Driessen C, Kiss von Soly S, Yakes F M, Wustrow D, Shawver L, Zhou H J, Martin T G, Wolf J L, Mitsiades C S, Anderson D J, Rolfe M. The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma. Mol Cancer Ther 2017; 16:2375-2386.
   
Zander T, Aebi S, Pabst T, Renner C, Driessen C. Spotlight on pomalidomide: could less be more?. Leukemia 2017; 31:1987-1989.
   
Besse L, Kraus M, Besse A, Bader J, Silzle T, Mehrling T, Driessen C. The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways. Blood Cancer J 2017; 7:e589.
   
Moreau P, van de Donk N W C J, Miguel J S, Lokhorst H, Nahi H, Ben-Yehuda D, Cavo M, Cook G, Delforge M, Einsele H, Zweegman S, Ludwig H, Driessen C, Palumbo A, Facon T, Plesner T, Dimopoulos M, Sondergeld P, Sonneveld P, Mateos M V. Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. Drugs 2016; 76:989-990.
   
Xin B T, Schimmack G, Du Y, Florea B I, van der Marel G A, Driessen C, Krappmann D, Overkleeft H S. Development of new Malt1 inhibitors and probes. Bioorg Med Chem 2016; 24:3312-29.
   
Yong K, Delforge M, Driessen C, Fink L, Flinois A, Gonzalez-McQuire S, Safaei R, Karlin L, Mateos M V, Raab M S, Schoen P, Cavo M. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol 2016; 175:252-264.
   
Mey U J M, Brugger W, Schwarb H, Pederiva S, Schwarzer A, Dechow T, Jehner P, Rauh J, Taverna C J, Schmid M, Schmidt-Hieber M, Doerfel S, Fischer N, Ruefer A, Ziske C, Knauf W, Cathomas R, von Moos R, Hitz F, Sauter R, Hiendlmeyer E, Cantoni N, Bargetzi M, Driessen C. Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2(nd) -line therapy for relapsed and refractory multiple myeloma - a phase II trial. Br J Haematol 2016;.
   
Raab M S, Cavo M, Delforge M, Driessen C, Fink L, Flinois A, Gonzalez-McQuire S, Safaei R, Karlin L, Mateos M V, Schoen P, Yong K. Multiple myeloma: practice patterns across Europe. Br J Haematol 2016; 175:66-76.
   
Soriano G P, Besse L, Li N, Kraus M, Besse A, Meeuwenoord N, Bader J, Everts B, den Dulk H, Overkleeft H S, Florea B I, Driessen C. Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism. Leukemia 2016; 30:2198-2207.
   
Moreau P, van de Donk N W C J, San Miguel J, Lokhorst H, Nahi H, Ben-Yehuda D, Cavo M, Cook G, Delforge M, Einsele H, Zweegman S, Ludwig H, Driessen C, Palumbo A, Facon T, Plesner T, Dimopoulos M, Sondergeld P, Sonneveld P, Mateos M V. Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. Drugs 2016; 76:853-67.
   
Xin B T, de Bruin G, Huber E M, Besse A, Florea B I, Filippov D V, van der Marel G A, Kisselev A F, van der Stelt M, Driessen C, Groll M, Overkleeft H S. Structure-Based Design of β5c Selective Inhibitors of Human Constitutive Proteasomes. J Med Chem 2016; 59:7177-87.
   
Mamot C, Klingbiel D, Hitz F, Renner C, Pabst T, Driessen C, Mey U, Pless M, Bargetzi M, Krasniqi F, Gigli F, Hany T, Samarin A, Biaggi C, Rusterholz C, Dirnhofer S, Zucca E, Martinelli G. Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07). J Clin Oncol 2015; 33:2523-9.
   
de Bruin G, Xin B T, Kraus M, van der Stelt M, van der Marel G A, Kisselev A F, Driessen C, Florea B I, Overkleeft H S. A Set of Activity-Based Probes to Visualize Human (Immuno)proteasome Activities. Angew Chem Int Ed Engl 2015; 55:4199-203.
   
Kraus M, Bader J, Geurink P P, Weyburne E S, Mirabella A C, Silzle T, Shabaneh T B, van der Linden W A, de Bruin G, haile s, van Rooden E, Appenzeller C, Li N, Kisselev A F, Overkleeft H, Driessen C. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells. Haematologica 2015; 100:1350-60.
   
Mey U J M, Leitner C, Driessen C, Cathomas R, Klingbiel D, Hitz F. Improved survival of older patients with multiple myeloma in the era of novel agents. Hematol Oncol 2015; 34:217-223.
   
Driessen C, Kraus M, Joerger M, Rosing H, Bader J, Hitz F, Berset C, Xyrafas A, Hawle H, Berthod G, Overkleeft H S, Sessa C, Huitema A, Pabst T, von Moos R, Hess D, Mey U J M. Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08). Haematologica 2015; 101:346-55.
   
Tornatore L, Sandomenico A, Raimondo D, Low C, Rocci A, Tralau-Stewart C, Capece D, D'Andrea D, Bua M, Boyle E, van Duin M, Zoppoli P, Jaxa-Chamiec A, Thotakura A K, Dyson J, Walker B A, Leonardi A, Chambery A, Driessen C, Sonneveld P, Morgan G, Palumbo A, Tramontano A, Rahemtulla A, Ruvo M, Franzoso G. Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors. Cancer Cell 2014; 26:495-508.
   
de Bruin G, Huber E M, Xin B T, van Rooden E J, Al-Ayed K, Kim K B, Kisselev A F, Driessen C, van der Stelt M, van der Marel G A, Groll M, Overkleeft H S. Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes. J Med Chem 2014; 57:6197-209.
   
Engelhardt M, Terpos E, Kleber M, Gay F, Wäsch R, Morgan G, Cavo M, van de Donk N, Beilhack A, Bruno B, Johnsen H E, Hájek R, Driessen C, Ludwig H, Beksac M, Boccadoro M, Straka C, Brighen S, Gramatzki M, Larocca A, Lokhorst H, Magarotto V, Morabito F, Dimopoulos M A, Einsele H, Sonneveld P, Palumbo A, European Myeloma Network . European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica 2014; 99:232-42.
   
Kraus M, Bader J, Overkleeft H, Driessen C. Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance. Blood Cancer J 2013; 3:e103.
   
Kraus M, Müller-Ide H, Rückrich T, Bader J, Overkleeft H, Driessen C. Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations. Leuk Res 2013; 38:383-92.
   
Gallerani E, Zucchetti M, Brunelli D, Marangon E, Noberasco C, hess u, Delmonte A, Martinelli G, Böhm S, Driessen C, De Braud F, Marsoni S, Cereda R, Sala F, D'Incalci M, Sessa C. A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma. Eur J Cancer 2012; 49:290-6.
   
Hundsberger T, Cogliatti S B, Kleger G R, fretz c, Gähler A, anliker m, fournier j, von Moos R, Tettenborn B, Driessen C. Intravascular lymphoma mimicking cerebral stroke: report of two cases. Case Rep Neurol 2011; 3:278-283.
   
Engelhardt M, Udi J, Kleber M, Spencer A, Rocci A, Knop S, Bruno B, Bringhen S, Pérez-Simón J A, Zweegman S, Driessen C, Patriarca F, Gramatzki M, Terpos E, Sezer O, Kropff M, Straka C, Johnsen H E, Waage A, Boegsted M, Lokhorst H, Hájek R, Morgan G, Boccadoro M, Ludwig H, Cavo M, Polliack A, Sonneveld P, Einsele H, Palumbo A. European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. Leuk Lymphoma 2010; 51:2006-11.
   
Rückrich T, Kraus M, Gogel J, Beck A, Ovaa H, Verdoes M, Overkleeft H S, Kalbacher H, Driessen C. Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2009; 23:1098-105.
   
Harman A N, Kraus M, Bye C R, Byth K, Turville S G, Tang O, Mercier S K, Nasr N, Stern J L, Slobedman B, Driessen C, Cunningham A L. HIV-1-infected dendritic cells show 2 phases of gene expression changes, with lysosomal enzyme activity decreased during the second phase. Blood 2009; 114:85-94.
   
Clerc J, Florea B I, Kraus M, Groll M, Huber R, Bachmann A S, Dudler R, Driessen C, Overkleeft H S, Kaiser M. Syringolin A selectively labels the 20 S proteasome in murine EL4 and wild-type and bortezomib-adapted leukaemic cell lines. Chembiochem : a European journal of chemical biology 2009; 10:2638-43.
   
Hillaert U, Verdoes M, Florea B I, Saragliadis A, Saragliadis A, Habets K L L, Kuiper J, Van Calenbergh S, Ossendorp F, van der Marel G A, Driessen C, Overkleeft H S. Receptor-mediated targeting of cathepsins in professional antigen presenting cells. Angewandte Chemie (International ed. in English) 2009; 48:1629-32.
   
Fissolo N, Kraus M, Reich M, Ayturan M, Overkleeft H, Driessen C, Weissert R. Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation. European journal of immunology 2008; 38:2401-11.
   
Horger M, Pereira P, Claussen C D, Kanz L, Vonthein R, Denecke B, Driessen C. Hyperattenuating bone marrow abnormalities in myeloma patients using whole-body non-enhanced low-dose MDCT: correlation with haematological parameters. The British journal of radiology 2008; 81:386-96.
   
Kessler T, Reich M, Jahn G, Tolosa E, Beck A, Kalbacher H, Overkleeft H, Schempp S, Driessen C. Human cytomegalovirus infection interferes with major histocompatibility complex type II maturation and endocytic proteases in dendritic cells at multiple levels. The Journal of general virology 2008; 89:2427-36.
   
Schulz H, Rehwald U, Morschhauser F, Elter T, Driessen C, Rüdiger T, Borchmann P, Schnell R, Diehl V, Engert A, Reiser M. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 2008; 111:109-11.
   
Busse A, Kraus M, Na I K, Rietz A, Scheibenbogen C, Driessen C, Blau I W, Thiel E, Keilholz U. Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits. Cancer 2008; 112:659-70.
   
Kraus M, Malenke E, Gogel J, Müller H, Rückrich T, Overkleeft H, Ovaa H, Koscielniak E, Hartmann J T, Driessen C. Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis. Molecular cancer therapeutics 2008; 7:1940-8.
   
Zaidi N, Burster T, Sommandas V, Herrmann T, Boehm B O, Driessen C, Voelter W, Kalbacher H. A novel cell penetrating aspartic protease inhibitor blocks processing and presentation of tetanus toxoid more efficiently than pepstatin A. Biochemical and biophysical research communications 2007; 364:243-9.
   
Kraus M, Rückrich T, Reich M, Gogel J, Beck A, Kammer W, Berkers C R, Burg D, Overkleeft H, Ovaa H, Driessen C. Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007; 21:84-92.
   
Burster T, Marin-Esteban V, Boehm B O, Dunn S, Rotzschke O, Falk K, Weber E, Verhelst S H L, Kalbacher H, Driessen C. Design of protease-resistant myelin basic protein-derived peptides by cleavage site directed amino acid substitutions. Biochemical pharmacology 2007; 74:1514-23.
   
Reich M, van Swieten P F, Sommandas V, Kraus M, Fischer R, Weber E, Kalbacher H, Overkleeft H S, Driessen C. Endocytosis targets exogenous material selectively to cathepsin S in live human dendritic cells, while cell-penetrating peptides mediate nonselective transport to cysteine cathepsins. Journal of leukocyte biology 2007; 81:990-1001.
   
Burster T, Beck A, Poeschel S, Øren A, Baechle D, Reich M, Roetzschke O, Falk K, Boehm B O, Youssef S, Kalbacher H, Overkleeft H, Tolosa E, Driessen C. Interferon-gamma regulates cathepsin G activity in microglia-derived lysosomes and controls the proteolytic processing of myelin basic protein in vitro. Immunology 2007; 121:82-93.
   
Zaidi N, Herrmann T, Baechle D, Schleicher S, Gogel J, Driessen C, Voelter W, Kalbacher H. A new approach for distinguishing cathepsin E and D activity in antigen-processing organelles. The FEBS journal 2007; 274:3138-49.
   
Horger M, Kanz L, Denecke B, Vonthein R, Pereira P, Claussen C D, Driessen C. The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma. Cancer 2007; 109:1617-26.
   
Horger M, Brodoefel H, Driessen C. [Extramedullary myeloma manifestations: imaging findings]. RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin 2006; 178:747-51.
   
Dengjel J, Schoor O, Fischer R, Reich M, Kraus M, Müller M, Kreymborg K, Altenberend F, Brandenburg J, Kalbacher H, Brock R, Driessen C, Rammensee H G, Stevanovic S. Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. Proceedings of the National Academy of Sciences of the United States of America 2005; 102:7922-7.
   
Baechle D, Cansier A, Fischer R, Brandenburg J, Burster T, Driessen C, Kalbacher H. Biotinylated fluorescent peptide substrates for the sensitive and specific determination of cathepsin D activity. Journal of peptide science : an official publication of the European Peptide Society 2005; 11:166-74.
   
Burster T, Beck A, Tolosa E, Schnorrer P, Weissert R, Reich M, Kraus M, Kalbacher H, Häring H U, Weber E, Overkleeft H, Driessen C. Differential processing of autoantigens in lysosomes from human monocyte-derived and peripheral blood dendritic cells. Journal of immunology (Baltimore, Md. : 1950) 2005; 175:5940-9.
   
van Zutphen S, Kraus M, Driessen C, van der Marel G A, Overkleeft H S, Reedijk J. Probing the potential of platinum(II) complexes for the inhibition of thiol-dependent enzymatic activity. Journal of inorganic biochemistry 2005; 99:1384-9.
   
van Swieten P F, Maehr R, van den Nieuwendijk A M C H, Kessler B M, Reich M, Wong C S, Kalbacher H, Leeuwenburgh M A, Driessen C, van der Marel G A, Ploegh H L, Overkleeft H S. Development of an isotope-coded activity-based probe for the quantitative profiling of cysteine proteases. Bioorganic & medicinal chemistry letters 2004; 14:3131-4.
   
Lautwein A, Kraus M, Reich M, Burster T, Brandenburg J, Overkleeft H S, Schwarz G, Kammer W, Weber E, Kalbacher H, Nordheim A, Driessen C. Human B lymphoblastoid cells contain distinct patterns of cathepsin activity in endocytic compartments and regulate MHC class II transport in a cathepsin S-independent manner. Journal of leukocyte biology 2004; 75:844-55.
   
Burster T, Beck A, Tolosa E, Marin-Esteban V, Rötzschke O, Falk K, Lautwein A, Reich M, Brandenburg J, Schwarz G, Wiendl H, Melms A, Lehmann R, Stevanovic S, Kalbacher H, Driessen C. Cathepsin G, and not the asparagine-specific endoprotease, controls the processing of myelin basic protein in lysosomes from human B lymphocytes. Journal of immunology (Baltimore, Md. : 1950) 2004; 172:5495-503.
   
Greiner A, Lautwein A, Overkleeft H S, Weber E, Driessen C. Activity and subcellular distribution of cathepsins in primary human monocytes. Journal of leukocyte biology 2003; 73:235-42.
   
Wiendl H, Lautwein A, Mitsdörffer M, Krause S, Erfurth S, Wienhold W, Morgalla M, Weber E, Overkleeft H S, Lochmüller H, Melms A, Tolosa E, Driessen C. Antigen processing and presentation in human muscle: cathepsin S is critical for MHC class II expression and upregulated in inflammatory myopathies. Journal of neuroimmunology 2003; 138:132-43.
   
Tolosa E, Li W, Yasuda Y, Wienhold W, Denzin L K, Lautwein A, Driessen C, Schnorrer P, Weber E, Stevanovic S, Kurek R, Melms A, Bromme D. Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis. The Journal of clinical investigation 2003; 112:517-26.
   
Rehwald U, Schulz H, Reiser M, Sieber M, Staak J O, Morschhauser F, Driessen C, Rudiger T, Muller-Hermelink K, Diehl V, Engert A, German Hodgkin Lymphoma Study Group (GHSG) . Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood 2003; 101:420-4.
   
Schwarz G, Brandenburg J, Reich M, Burster T, Driessen C, Kalbacher H. Characterization of legumain. Biological chemistry 2002; 383:1813-6.
   
Scheding S, Bergmann M, Shimosaka A, Wolff P, Driessen C, Rathke G, Jaschonek K, Brugger W, Kanz L. Human plasma thrombopoietin levels are regulated by binding to platelet thrombopoietin receptors in vivo. Transfusion 2002; 42:321-7.
   
Plüger E B E, Boes M, Alfonso C, Schröter C J, Kalbacher H, Ploegh H L, Driessen C. Specific role for cathepsin S in the generation of antigenic peptides in vivo. European journal of immunology 2002; 32:467-76.
   
Lautwein A, Burster T, Lennon-Duménil A M, Overkleeft H S, Weber E, Kalbacher H, Driessen C. Inflammatory stimuli recruit cathepsin activity to late endosomal compartments in human dendritic cells. European journal of immunology 2002; 32:3348-57.
   
Beck H, Schwarz G, Schröter C J, Deeg M, Baier D, Stevanovic S, Weber E, Driessen C, Kalbacher H. Cathepsin S and an asparagine-specific endoprotease dominate the proteolytic processing of human myelin basic protein in vitro. European journal of immunology 2001; 31:3726-36.
   
Driessen C, Lennon-Duménil A M, Ploegh H L. Individual cathepsins degrade immune complexes internalized by antigen-presenting cells via Fcgamma receptors. European journal of immunology 2001; 31:1592-601.
   
Lennon-Duménil A M, Roberts R A, Valentijn K, Driessen C, Overkleeft H S, Erickson A, Peters P J, Bikoff E, Ploegh H L, Wolf Bryant P. The p41 isoform of invariant chain is a chaperone for cathepsin L. The EMBO journal 2001; 20:4055-64.
   
Riese R J, Shi G P, Villadangos J, Stetson D, Driessen C, Lennon-Dumenil A M, Chu C L, Naumov Y, Behar S M, Ploegh H, Locksley R, Chapman H A. Regulation of CD1 function and NK1.1(+) T cell selection and maturation by cathepsin S. Immunity 2001; 15:909-19.
   
Villadangos J A, Driessen C, Shi G P, Chapman H A, Ploegh H L. Early endosomal maturation of MHC class II molecules independently of cysteine proteases and H-2DM. The EMBO journal 2000; 19:882-91.
   
Shi G P, Bryant R A, Riese R, Verhelst S, Driessen C, Li Z, Bromme D, Ploegh H L, Chapman H A. Role for cathepsin F in invariant chain processing and major histocompatibility complex class II peptide loading by macrophages. The Journal of experimental medicine 2000; 191:1177-86.
   
Driessen C, Bryant R A, Lennon-Duménil A M, Villadangos J A, Bryant P W, Shi G P, Chapman H A, Ploegh H L. Cathepsin S controls the trafficking and maturation of MHC class II molecules in dendritic cells. The Journal of cell biology 1999; 147:775-90.
   
Villadangos J A, Bryant R A, Deussing J, Driessen C, Lennon-Duménil A M, Riese R J, Roth W, Saftig P, Shi G P, Chapman H A, Peters C, Ploegh H L. Proteases involved in MHC class II antigen presentation. Immunological reviews 1999; 172:109-20.
   
Wellinghausen N, Driessen C, Rink L. Stimulation of human peripheral blood mononuclear cells by zinc and related cations. Cytokine 1996; 8:767-71.
   
Driessen C, Hirv K, Kirchner H, Rink L. Divergent effects of zinc on different bacterial pathogenic agents. The Journal of infectious diseases 1995; 171:486-9.
   
Driessen C, Hirv K, Wellinghausen N, Kirchner H, Rink L. Influence of serum on zinc, toxic shock syndrome toxin-1, and lipopolysaccharide-induced production of IFN-gamma and IL-1 beta by human mononuclear cells. Journal of leukocyte biology 1995; 57:904-8.
   
Driessen C, Hirv K, Kirchner H, Rink L. Zinc regulates cytokine induction by superantigens and lipopolysaccharide. Immunology 1995; 84:272-7.
   
Driessen C, Hirv K, Rink L, Kirchner H. Induction of cytokines by zinc ions in human peripheral blood mononuclear cells and separated monocytes. Lymphokine and cytokine research 1994; 13:15-20.
   
Rückrich T, Brandenburg J, Cansier A, Müller M, Stevanović S, Schilling K, Wiederanders B, Beck A, Melms A, Reich M, Driessen C, Kalbacher H. Specificity of human cathepsin S determined by processing of peptide substrates and MHC class II-associated invariant chain. Biol Chem 387:1503-11.
   
 
page 1 of 2